Next Article in Journal
Lean Six Sigma: Application of the Methodology in Data Processing for Cancer Registry
Previous Article in Journal
Healthcare Quality Indicators as a Tool for Safeguarding Patients with Limited Capacity and Physician Rights
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Proceeding Paper

In Silico Study of Mangrove Triterpenoids as SARS-CoV-2 Main Protease Inhibitors †

by
Ramamoorthy Purushothaman
*,
Ganapathy Vishnuram
and
Thirugnanasambandam Ramanathan
Centre of Advanced Study in Marine Biology, Faculty of Marine Sciences, Annamalai University, Parangipettai 608502, Tamil Nadu, India
*
Author to whom correspondence should be addressed.
Presented at the 2nd International Electronic Conference on Biomedicines, 1–31 March 2023; Available online: https://ecb2023.sciforum.net/.
Med. Sci. Forum 2023, 21(1), 45; https://doi.org/10.3390/ECB2023-14332
Published: 29 June 2023
(This article belongs to the Proceedings of The 2nd International Electronic Conference on Biomedicines)

Abstract

:
Aim: In the present study, we performed an in silico study on the triterpenoid compounds from the mangrove plant as potential COVID-19 main protease (Mpro) inhibitors, which can be used as a potential medicine target. Methods: In this study we performed molecular docking using AutoDock software. Results: The binding energies obtained through the docking of 6LU7 with beta-amyrin, betulin, germanicol, taraxerol, lupeol, lupane, simiarenol, tirucallol, ursolic acid, oleanolic acid, and alpha-amyrin were -8.37, −8.73, −8.06, −7.71, −8.32, −8.49, −8.16, −8.99, −9.24, −8.87, and −8.89 kcal/mol, respectively. Further, these results were also confirmed with drug-likeness properties by using Swiss ADME software. Conclusion: This study showed that triterpenoid compounds seemed to have the best potential to act as COVID-19 Mpro inhibitors, and that they contain a potential lead compound for the development of drugs, which can be used against SARS-CoV-2.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of COVID-19, a highly contagious illness that affects several sections of the respiratory system, and particularly the lungs [1,2]. There is not a specific treatment for COVID-19 at the moment [3]. Computationally aided drug design (CADD) methodologies have revealed significant implications for current research, and these procedures are quicker and more affordable [4]. In order to reduce the risk of wasting time and money, in silico approaches are used early on in the drug development process [5]. To manage SARS-CoV-2 infection, lead compounds derived from natural sources are thought to have fewer adverse effects and are considered to be inexpensive nutraceuticals [6]. The major subject of this investigation was mangrove-derived triterpenoid chemicals. Mangroves are either little trees or plants that thrive in rocky or muddy soils near brackish or salty coastal waters. Mangroves are facultative halophytes because they can tolerate salt and easily adapt to the harsh coastal environment [7]. Mangrove plants are abundant in new chemical compounds and natural products, which is becoming more common knowledge. Mangroves have received a great deal of scientific attention because of their strong ability to combat numerous ailments. Terpenoids make up more than 16% of the phytoconstituents in mangroves. Triterpenoids, which have 30 carbon atoms and are polymerized to create six isoprene units, are the most typical class of phytochemicals. In nature, triterpenoids are extensively dispersed. The variety of triterpenes and their extensive spectrum of pharmacological actions are closely connected. Triterpenes are conventionally used as anti-inflammatory, analgesic, hepatoprotective, cardiotonic, and sedative drugs in Asian countries [8]. Using molecular docking, we looked at triterpenoid chemicals that had been previously identified as being found in mangroves as potential inhibitors of the COVID-19 primary protease Mpro. The process of creating drugs to combat COVID-19 will benefit from these discoveries.

2. Materials and Methods

2.1. Protein Preparation

The main protease of SARS COVID-19 is Mpro, and its 3D structure was obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) in PDB format. The PDB is a library for the crystal structures of biological macromolecules [9] (PDB ID: 6LU7).

2.2. Ligand Preparation

The 3D structures of triterpenoid compounds from mangroves were obtained from the PubChem website in SDF format. Triterpenoid compounds like beta-amyrin (CID_73145), betulin (CID_72326), germanicol (CID_122857), taraxerol (CID_92097), lupeol (CID_259846), lupane (CID_9548715), simiarenol (CID_12442794), tirucallol (CID_101257), ursolic acid (CID_64945), oleanolic acid (CID_10494), and alpha-amyrin (CID_73170) were used in this study.
Drug-like properties were calculated using Lipinski’s rule of five [10,11]. Adherence to Lipinski’s rule of five was calculated using SWISSADME prediction.

2.3. Molecular Docking

The study was supported by tools like AutoDock, MGL, and Rasmol. The docking analyses were performed using AutoDock, Pymol, and Biovia Discovery Studio.

3. Results

3.1. Selection of Phytochemicals

A total of 12 compounds were selected based on adherence to Lipinski’s rule of five. They can be used in molecular docking experiments with the target protein 6LU7. The drug scanning results (Table 1) showed that all tested compounds in this study were accepted by Lipinski’s rule of five. The 2D diagrammatic representations (Table 1) of the selected triterpenoid compounds demonstrate interactions with the target protein Mpro. The 2D visualization of docking analysis results, including the H-bonds that interact with 6LU7 amino acids, is mentioned in Table 1.

3.2. Molecular Docking of Selected Compounds

Table 2 shows the molecular docking analysis results for the standard drug and 11 triterpenoid compounds against the main protease of SARS COVID-19 (6LU7). The binding energies obtained from the docking of 6LU7 with nelfinavir, beta-amyrin, betulin, germanicol, taraxerol, lupeol, lupane, simiarenol, tirucallol, ursolic acid, oleanolic acid, and alpha-amyrin were −6.21, −8.37, −8.73, −8.06, −7.71, −8.32, −8.49, −8.16, −8.99, −9.24, −8.87, and −8.89 kcal/mol, respectively. The visualization of 6LU7 binding with the selected triterpenoid compounds from the mangrove, including beta-amyrin, betulin, germanicol, taraxerol, lupeol, lupane, simiarenol, tirucallol, ursolic acid, oleanolic acid, and alpha-amyrin, as well as with nelfinavir (standard drug), is represented in Figure 1A to 1L as potential inhibitors of the COVID-19 Mpro.

4. Discussion

With 6LU7, nelfinavir creates several chemical connections, such as hydrogen and hydrophobic bonds. These triterpenoid chemicals have been abandoned in mangroves, according to several studies (Table 3). Similar to nelfinavir, the triterpenoid molecules from this study also created many chemical connections. The results show that compared to other molecules, ursolic acid bonds have a stronger affinity. According to their affinity, ursolic acid, tirucallol, alpha-amyrin, oleanolic acid, lupane, beta-amyrin, germanicol, simiarenol, betulin, taraxerol, and nelfinavir were the compounds with the greatest potential for inhibition in the current study’s docking analysis. The chemicals that are most suggested as potential COVID-19 Mpro inhibitors are mangrove triterpenoids, which should be investigated in further studies.

5. Conclusions

This investigation looked at a number of mangrove-derived triterpenoid chemicals that might be used to block the COVID-19 infection pathway. The compounds with the best binding energies and inhibition constants are beta-amyrin, betulin, germanicol, taraxerol, lupeol, lupane, simiarenol, tirucallol, ursolic acid, oleanolic acid, and alpha-amyrin. Compared to other molecules, ursolic acid bonds have a stronger affinity. Triterpenoids were therefore the substances found in mangroves that are most recommended as potential COVID-19 Mpro inhibitors. For the development of medicine from mangroves, additional clinical trials examining the potential of terpenoid chemicals against viral infection must be conducted, and should be followed by in vitro and in vivo research.

Author Contributions

R.P. and G.V. written the first draft of the complete manuscript and conceived the research idea T.R. commented on the previous versions of the manuscript. All authors contributed to the review and editing of 2nd and 3rd draft of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by TANSCHE-RGP, and the author R.P. received research support from TANSCHE-RGP. Grant No: RGP/2019-20/AMU/HECP-0054.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We would like to acknowledge the authorities of Annamalai University, Portonovo, Tamil Nadu, India, the Department of Science and Technology-Science and Engineering Research Board, Tamil Nadu Forest Department. and TANSCHE, Tamil Nadu, India. for all their support in carrying out this work.

Conflicts of Interest

The authors have no conflict of interest.

References

  1. Malik, Y.S.; Sircar, S.; Bhat, S.; Sharun, K.; Dhama, K.; Dadar, M.; Tiwari, R.; Chaicumpa, W. Emerging novel coronavirus (2019-nCoV)—Current scenario, evolutionary perspective based on genome analysis and recent developments. Vet. Q. 2020, 40, 68–76. [Google Scholar] [CrossRef] [PubMed]
  2. Lee, P.I.; Hsueh, P.R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J. Microbiol. Immunol. Infect. 2020, 53, 365. [Google Scholar] [CrossRef] [PubMed]
  3. Rodríguez-Morales, A.J.; MacGregor, K.; Kanagarajah, S.; Patel, D.; Schlagenhauf, P. Going global–Travel and the 2019 novel coronavirus. Travel Med. Infect. Dis. 2020, 33, 101578. [Google Scholar] [CrossRef] [PubMed]
  4. Guerriero, G.; Berni, R.; Muñoz-Sanchez, J.A.; Apone, F.; Abdel-Salam, E.M.; Qahtan, A.A.; Alatar, A.A.; Cantini, C.; Cai, G.; Hausman, J.F.; et al. Production of plant secondary metabolites: Examples, tips and suggestions for biotechnologists. Genes 2018, 9, 309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Yang, L.; Wen, K.S.; Ruan, X.; Zhao, Y.X.; Wei, F.; Wang, Q. Response of plant secondary metabolites to environmental factors. Molecules 2018, 23, 762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Thayil, S.M.; Thyagarajan, S.P. Pa-9: A flavonoid extracted from plectranthus amboinicus inhibits HIV-1 protease. Int. J. Pharmacogn. Phytochem. Res. 2016, 8, 1020–1024. [Google Scholar]
  7. Wang, W.; Yan, Z.; You, S.; Zhang, Y.; Chen, L.; Lin, G. Mangroves: Obligate or facultative halophytes? A review. Trees 2011, 25, 953–963. [Google Scholar] [CrossRef]
  8. Bishayee, A.; Ahmed, S.; Brankov, N.; Perloff, M. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front. Biosci. A J. Virtual Libr. 2011, 16, 980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Rosidi, A.; Khomsan, A.; Setiawan, B.; Riyadi, H.; Briawan, D. Antioxidant potential of temulawak (Curcuma xanthorrhiza roxb). Pak. J. Nutr. 2016, 15, 556. [Google Scholar] [CrossRef] [Green Version]
  10. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2012, 64, 4–17. [Google Scholar] [CrossRef]
  11. Giménez, B.G.; Santos, M.S.; Ferrarini, M.; Fernandes, J.P.S. Evaluation of blockbuster drugs under the rule-of-five. Die Pharm. Int. J. Pharm. Sci. 2010, 65, 148–152. [Google Scholar]
Figure 1. 3D visualization of 6LU7 binding with beta-amyrin (A), betulin (B), germanicol (C), taraxerol (D), lupeol (E), lupine (F), simiarenol (G), tirucallol (H), ursolic acid (I), oleanolic acid (J), alpha-amyrin (K), and nelfinavir (L) using Biovia Discover Studio. The green and pink colors represent H-bond acceptor and donor regions, respectively.
Figure 1. 3D visualization of 6LU7 binding with beta-amyrin (A), betulin (B), germanicol (C), taraxerol (D), lupeol (E), lupine (F), simiarenol (G), tirucallol (H), ursolic acid (I), oleanolic acid (J), alpha-amyrin (K), and nelfinavir (L) using Biovia Discover Studio. The green and pink colors represent H-bond acceptor and donor regions, respectively.
Msf 21 00045 g001
Table 1. Properties of COVID-19 Mpro potential inhibitor candidates.
Table 1. Properties of COVID-19 Mpro potential inhibitor candidates.
S. No.Compound NameMolecular FormulaMolecular Structure and Interaction with 6LU7Lipinski’s Rule of Five
Properties Value
1.NelfinavirC32H45N3O4SMsf 21 00045 i001Molecular weight (<500 Da)567.78 g/mol
LogP (<5)4.33
H-Bond donor (5)4
H-bond acceptor (<10)5
Violation1
2.beta-AmyrinC30H50OMsf 21 00045 i002Molecular weight (<500 Da)426.72 g/mol
LogP (<5)4.63
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
3.BetulinC30H50O2Msf 21 00045 i003Molecular weight (<500 Da)442.72 g/mol
LogP (<5)4.47
H-Bond donor (5)2
H-bond acceptor (<10)2
Violation1
4.GermanicolC30H50OMsf 21 00045 i004Molecular weight (<500 Da)426.72 g/mol
LogP (<5)5.04
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
5.TaraxerolC30H50OMsf 21 00045 i005Molecular weight (<500 Da)426.72 g/mol
LogP (<5)4.73
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
6.LupeolC30H50OMsf 21 00045 i006Molecular weight (<500 Da)426.72 g/mol
LogP (<5)4.63
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
7.LupaneC30H52Msf 21 00045 i007Molecular weight (<500 Da)426.72 g/mol
LogP (<5)4.63
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
8.Simiarenol C30H50OMsf 21 00045 i008Molecular weight (<500 Da)426.72 g/mol
LogP (<5)4.63
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
9.Tirucallol C30H50OMsf 21 00045 i009Molecular weight (<500 Da)426.72 g/mol
LogP (<5)5.14
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
10.Ursolic acidC30H48O3Msf 21 00045 i010Molecular weight (<500 Da)456.70 g/mol
LogP (<5)5.82
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
11.Oleanolic acidC30H48O3Msf 21 00045 i011Molecular weight (<500 Da)456.70 g/mol
LogP (<5)5.82
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
12.alpha-Amyrin C30H50OMsf 21 00045 i012Molecular weight (<500 Da)426.72 g/mol
LogP (<5)6.92
H-Bond donor (5)1
H-bond acceptor (<10)1
Violation1
Table 2. Molecular docking analyses of triterpenoid compounds against 6LU7.
Table 2. Molecular docking analyses of triterpenoid compounds against 6LU7.
Protein LigandLowest Binding Energy (kcal/mol)Ligand Efficiency Inhibition ConstantIntermolecular Energy
(kcal/mol)
VDW-H Bond Desolvation Energy (kcal/mol)
6lu7Nelfinavir−6.21−9.70927.83 uM−9.79 −9.77
beta-Amyrin−8.08−4.4451.20 µM−8.37−8.33
Betulin−7.54−6.1612.96 µM−8.73−8.70
Germanicol−7.76−4.2292.04 µM−8.06−8.02
Taraxerol−7.41−25.6013.68 µM−7.71−7.43
Lupeol−7.73−10.7862.17 µM−8.32−8.31
Lupane−8.19−9.698996.23 nM−8.49−8.48
Simiarenol−7.56−10.0062.87 µM−8.16−8.15
Tirucallol−8.99−4.998255.21 nM−10.49−10.46
Ursolic acid−9.24−3.784168.90 nM−10.13−10.05
Oleanolic acid−8.87−5.134314.36 nM−9.77−9.69
alpha-Amyrin−8.89−11.721306.52 nM−9.18−9.14
Table 3. Triterpenoids compounds from mangrove.
Table 3. Triterpenoids compounds from mangrove.
Compounds Species NamePartsReferences
beta-AmyrinRhizophora mucronataBarkRohini, R.M et al., 2009
Betulin Rhizophora mucronataLeafGhosh A et al., 1985
Germanicol Rhizophora sp.LeafKoch, B.P et al., 2003
Taraxerol Avicennia marinaRootMahera, S.A et al., 2011
Lupeol Rhizophora mucronataBarkRohini, R.M et al., 2009
LupaneCeriops decandraLeaf Ponglimanont, C. and Thongdeeying, P., 2005
Simiarenol Rhizophora mucronataBarkRohini, R.M et al., 2009
TirucallolExcoecaria agallochaLeaf Zou, J.H et al., 2006
Ursolic acidBrugurera gymnorhizaLeafGhosh, A et al., 1985
Oleanolic acidAcanthus ilicifoliusLeafGhosh, A et al., 1985
alpha-AmyrinCeriops decandraLeaf Ghosh, A et al., 1985
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Purushothaman, R.; Vishnuram, G.; Ramanathan, T. In Silico Study of Mangrove Triterpenoids as SARS-CoV-2 Main Protease Inhibitors. Med. Sci. Forum 2023, 21, 45. https://doi.org/10.3390/ECB2023-14332

AMA Style

Purushothaman R, Vishnuram G, Ramanathan T. In Silico Study of Mangrove Triterpenoids as SARS-CoV-2 Main Protease Inhibitors. Medical Sciences Forum. 2023; 21(1):45. https://doi.org/10.3390/ECB2023-14332

Chicago/Turabian Style

Purushothaman, Ramamoorthy, Ganapathy Vishnuram, and Thirugnanasambandam Ramanathan. 2023. "In Silico Study of Mangrove Triterpenoids as SARS-CoV-2 Main Protease Inhibitors" Medical Sciences Forum 21, no. 1: 45. https://doi.org/10.3390/ECB2023-14332

APA Style

Purushothaman, R., Vishnuram, G., & Ramanathan, T. (2023). In Silico Study of Mangrove Triterpenoids as SARS-CoV-2 Main Protease Inhibitors. Medical Sciences Forum, 21(1), 45. https://doi.org/10.3390/ECB2023-14332

Article Metrics

Back to TopTop